Chelating Agents for Neurodegenerative Diseases

Author(s): R. J. Ward, D. T. Dexter, R. R. Crichton

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 17 , 2012

Become EABM
Become Reviewer
Call for Editor


It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson’s disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and ageassociated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer’s disease. We conclude with a brief summary of chelation therapy in AD.

Keywords: chelation, neurodegeneration, iron, copper, zinc

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 09 May, 2012
Page: [2760 - 2772]
Pages: 13
DOI: 10.2174/092986712800609689
Price: $65

Article Metrics

PDF: 42